Invivyd, Inc. (IVVD) shareholders
Close on Nov 17, 2026Market cap $151.09MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lampert Mark N Joint filing with Bvf Partners L P/Il (9.99%), Bvf Inc/Il (9.99%) and 3 more | 29,571,826 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more | 28,857,208 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (9.00%), Lampert Mark N (9.00%) and 1 more | 25,525,000 | 9.00% | 13G (passive) amendment | Dec 31, 2025 |
| Janus Henderson Group PLC Joint filing with Janus Henderson Biotech Innovation Master Fund Ltd (10.30%) | 25,383,077 | 12.10% | 13G (passive) amendment | Sep 30, 2025 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (7.90%), Joseph Edelman (7.90%) | 21,785,166 | 7.90% | 13G (passive) | Nov 18, 2025 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (7.00%), Rajeev Shah (7.00%) and 1 more | 21,342,442 | 7.00% | 13G (passive) amendment | Mar 31, 2026 |
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 21,338,288 | 9.90% | 13G (passive) | Aug 22, 2025 |
| Adimab, LLC | 20,262,170 | 7.30% | 13D (active) amendment | Dec 23, 2025 |
| Maverick Capital Management, LLC Joint filing with Maverick Capital, Ltd. (6.70%), Lee S. Ainslie III (6.70%) | 18,970,913 | 6.70% | 13G (passive) amendment | Dec 31, 2025 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (6.30%), Perceptive Life Sciences Master Fund, Ltd. (6.30%) | 18,490,636 | 6.30% | 13G (passive) amendment | Jun 30, 2026 |
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (6.00%), Point72 Capital Advisors, Inc. (6.00%) | 16,653,036 | 6.00% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 16,124,696 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Soleus GP, LLC Joint filing with Soleus Capital Management, L.P. (5.10%), Guy Levy (5.10%) | 10,850,000 | 5.10% | 13G (passive) | Oct 10, 2025 |
| Lee S. Ainslie III Joint filing with Maverick Capital, Ltd. (8.50%), Maverick Capital Management, LLC (8.50%) | 10,229,118 | 8.50% | 13G (passive) amendment | Jun 30, 2025 |
| David Kroin Joint filing with Deep Track Capital, LP (8.10%), Deep Track Biotechnology Master Fund, Ltd. (8.10%) | 9,722,254 | 8.10% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IVVD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 34,173,104 | 11.59% | $30.05M | New | 0.01% |
| Bvf Inc/Il | 28,165,000 | 9.56% | $24.57M | +8,640,000 | 0.63% |
| Maverick Capital Ltd | 18,970,913 | 6.44% | $16.55M | – | 0.15% |
| Perceptive Advisors LLC | 18,490,636 | 6.27% | $16.13M | −2,368,667 | 0.24% |
| BlackRock, Inc. | 16,134,885 | 5.47% | $14.08M | +11,853,095 | 0.00% |
| Vanguard Capital Management LLC | 10,496,507 | 3.56% | $9.15M | +422,181 | 0.00% |
| M28 Capital Management LP | 9,248,250 | 3.14% | $8.07M | – | 17.11% |
| Saturn V Capital Management LP | 8,392,288 | 2.85% | $7.32M | −2,556,796 | 1.05% |
| Soleus Capital Management, L.P. | 7,708,727 | 2.62% | $6.73M | – | 0.23% |
| Point72 Asset Management, L.P. | 7,542,061 | 2.56% | $6.58M | +7,498,130 | 0.01% |
| Morgan Stanley | 5,730,948 | 1.94% | $5.00M | +2,342,766 | 0.00% |
| Geode Capital Management, LLC | 5,418,774 | 1.84% | $4.73M | +2,949,847 | 0.00% |
| Siren, L.L.C. | 5,000,000 | 1.70% | $4.36M | +1,000,000 | 0.09% |
| Driehaus Capital Management LLC | 4,806,543 | 1.63% | $4.19M | −3,630,351 | 0.02% |
| ADAR1 Capital Management, LLC | 3,807,427 | 1.29% | $3.32M | −15,000 | 0.15% |
| Adage Capital Partners Gp, L.L.C. | 3,661,480 | 1.24% | $3.19M | – | 0.00% |
| Citadel Advisors LLC | 3,580,941 | 1.21% | $3.12M | +1,991,366 | 0.00% |
| State Street Corp | 3,457,428 | 1.17% | $3.02M | −3,478,220 | 0.00% |
| Qube Research & Technologies Ltd | 3,320,238 | 1.13% | $2.90M | +633,043 | 0.00% |
| Ikarian Capital, LLC | 2,656,570 | 0.90% | $2.32M | – | 0.25% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 125 | 233M | 79.0% | 34 / 38 | 26 / 45 | 80M | 42M |
| Q1 2026 | 140 | 228M | 77.5% | 42 / 40 | 25 / 16 | 42M | 43M |
| Q4 2025 | 116 | 240M | 81.5% | 49 / 27 | 18 / 8 | 115M | 12M |
| Q3 2025 | 78 | 149M | 50.5% | 26 / 21 | 17 / 16 | 102M | 14M |
| Q2 2025 | 68 | 60M | 20.5% | 17 / 13 | 26 / 28 | 4M | 13M |
| Q1 2025 | 79 | 70M | 23.9% | 17 / 21 | 26 / 14 | 3M | 9M |
| Q4 2024 | 77 | 77M | 26.1% | 13 / 23 | 20 / 12 | 14M | 8M |
| Q3 2024 | 76 | 72M | 24.3% | 15 / 18 | 23 / 17 | 6M | 6M |
| Q2 2024 | 80 | 76M | 25.8% | 23 / 28 | 18 / 29 | 13M | 10M |
| Q1 2024 | 86 | 73M | 24.6% | 32 / 25 | 18 / 5 | 20M | 3M |
| Q4 2023 | 59 | 56M | 18.9% | 11 / 18 | 16 / 10 | 6M | 4M |
| Q3 2023 | 58 | 53M | 18.1% | 9 / 12 | 20 / 8 | 4M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
65 funds held IVVD in Q2 2026, 79% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IVVD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 7,785,522 | 2.64% | $6.79M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 5,373,005 | 1.82% | $4.69M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,383,653 | 0.81% | $2.08M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,288,478 | 0.78% | $1.22M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 2,025,862 | 0.69% | $1.77M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,103,785 | 0.37% | $1.26M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 706,398 | 0.24% | $616.26K | 0.04% | Jun 30, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 585,533 | 0.20% | $510.82K | 0.00% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 538,493 | 0.18% | $288.09K | 0.00% | Jul 31, 2026 |
| Emerald Growth Fund | 428,847 | 0.15% | $600.39K | 0.04% | Apr 30, 2026 |
| Emerald Growth Fund | 428,847 | 0.15% | $229.43K | 0.02% | Jul 31, 2026 |
| Virtus Biotech Clinical Trials Etf | 403,655 | 0.14% | $215.96K | 0.47% | Jul 31, 2026 |
| Master Small Cap Index Series | 393,460 | 0.13% | $343.25K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 390,357 | 0.13% | $445.01K | 0.00% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 353,119 | 0.12% | $188.92K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marc Elia | Chief Executive Officer, Director | 9,248,250 | 3.14% | Sep 1, 2026 |
| William E. Duke | Chief Financial Officer | 168,937 | 0.06% | Aug 18, 2026 |
| Robert D. Allen III | Chief Scientific Officer | 178,765 | 0.06% | Aug 18, 2026 |
| Jill Andersen | Chief Legal Officer, Secretary | 284,274 | 0.10% | Aug 18, 2026 |
| Timothy Edward Lee | Chief Commercial Officer | 178,937 | 0.06% | Aug 18, 2026 |
| Julie Green | Chief Human Resources Officer | 168,937 | 0.06% | Aug 18, 2026 |
| Michael Mina | CMO and Chief Epidemiologist | – | – | Aug 4, 2026 |
| Ian Sheffield | Director | – | – | Sep 2, 2026 |
| Terrance McGuire | Director | 3,066,757 | 1.04% | May 21, 2026 |
| Kevin F. McLaughlin | Director | 50,000 | 0.02% | May 21, 2026 |
| Paul Bolno | Director | – | – | May 21, 2026 |
| Ajay Royan | Director | 11,241,580 | 3.81% | May 21, 2026 |
| Tamsin Berry | Director | – | – | May 21, 2026 |
| Christine Lindenboom | Director | – | – | May 22, 2025 |
| Capital Management LP M28 | – | 6,398,250 | 2.17% | May 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Julie Green Chief Human Resources Officer | Aug 18, 2026 | Sale(10b5-1 plan) | −18,425 | $0.84 | $15.48K | 168,937 |
| Timothy Edward Lee Chief Commercial Officer | Aug 18, 2026 | Sale(10b5-1 plan) | −18,425 | $0.84 | $15.48K | 178,937 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 18, 2026 | Sale(10b5-1 plan) | −30,706 | $0.84 | $25.79K | 283,774 |
| Robert D. Allen III Chief Scientific Officer | Aug 18, 2026 | Sale(10b5-1 plan) | −17,043 | $0.84 | $14.32K | 178,765 |
| William E. Duke Chief Financial Officer | Aug 18, 2026 | Sale(10b5-1 plan) | −18,425 | $0.84 | $15.48K | 168,937 |
| Julie Green Chief Human Resources Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −22,355 | $0.72 | $16.10K | 187,362 |
| Timothy Edward Lee Chief Commercial Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −22,355 | $0.72 | $16.10K | 197,362 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 17, 2026 | Sale(10b5-1 plan) | −37,256 | $0.72 | $26.82K | 314,480 |
| Robert D. Allen III Chief Scientific Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −20,679 | $0.72 | $14.89K | 195,808 |
| William E. Duke Chief Financial Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −22,355 | $0.72 | $16.10K | 187,362 |
| Julie Green Chief Human Resources Officer | Aug 15, 2026 | Option exercise | +102,000 | – | – | 209,717 |
| Timothy Edward Lee Chief Commercial Officer | Aug 15, 2026 | Option exercise | +102,000 | – | – | 219,717 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 15, 2026 | Option exercise | +170,000 | – | – | 351,736 |
| Robert D. Allen III Chief Scientific Officer | Aug 15, 2026 | Option exercise | +102,000 | – | – | 216,487 |
| William E. Duke Chief Financial Officer | Aug 15, 2026 | Option exercise | +102,000 | – | – | 209,717 |
| Robert D. Allen III Chief Scientific Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −19,392 | $1.58 | $30.64K | 114,487 |
| William E. Duke Chief Financial Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −20,964 | $1.58 | $33.12K | 107,717 |
| Julie Green Chief Human Resources Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −20,964 | $1.58 | $33.12K | 107,717 |
| Jill Andersen Chief Legal Officer, Secretary | Feb 18, 2026 | Sale(10b5-1 plan) | −34,939 | $1.58 | $55.20K | 181,736 |
| Timothy Edward Lee Chief Commercial Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −20,964 | $1.58 | $33.12K | 117,717 |
| Robert D. Allen III Chief Scientific Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −18,189 | $1.54 | $28.01K | 133,879 |
| William E. Duke Chief Financial Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −19,663 | $1.54 | $30.28K | 128,681 |
| Julie Green Chief Human Resources Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −19,663 | $1.54 | $30.28K | 128,681 |
| Jill Andersen Chief Legal Officer, Secretary | Feb 17, 2026 | Sale(10b5-1 plan) | −32,771 | $1.54 | $50.47K | 216,675 |
| Timothy Edward Lee Chief Commercial Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −19,663 | $1.54 | $30.28K | 138,681 |
| Robert D. Allen III Chief Scientific Officer | Feb 15, 2026 | Option exercise | +99,000 | – | – | 152,068 |
| William E. Duke Chief Financial Officer | Feb 15, 2026 | Option exercise | +99,000 | – | – | 148,344 |
| Julie Green Chief Human Resources Officer | Feb 15, 2026 | Option exercise | +99,000 | – | – | 148,344 |
| Jill Andersen Chief Legal Officer, Secretary | Feb 15, 2026 | Option exercise | +165,000 | – | – | 249,446 |
| Timothy Edward Lee Chief Commercial Officer | Feb 15, 2026 | Option exercise | +99,000 | – | – | 158,344 |
| Kevin F. McLaughlin Director | Nov 19, 2025 | Buy | +50,000 | $2.50 | $125.00K | 50,000 |
| Timothy Edward Lee Chief Commercial Officer | Aug 19, 2025 | Sale(10b5-1 plan) | −29,643 | $0.57 | $16.90K | 59,344 |
| Julie Green Chief Human Resources Officer | Aug 19, 2025 | Sale(10b5-1 plan) | −29,643 | $0.57 | $16.90K | 49,344 |
| Robert D. Allen III Chief Scientific Officer | Aug 19, 2025 | Sale(10b5-1 plan) | −27,420 | $0.57 | $15.63K | 53,068 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 19, 2025 | Sale(10b5-1 plan) | −49,402 | $0.57 | $28.16K | 84,446 |
| William E. Duke Chief Financial Officer | Aug 19, 2025 | Sale(10b5-1 plan) | −29,643 | $0.57 | $16.90K | 49,344 |
| Timothy Edward Lee Chief Commercial Officer | Aug 18, 2025 | Sale(10b5-1 plan) | −20,013 | $0.65 | $13.01K | 88,987 |
| Julie Green Chief Human Resources Officer | Aug 18, 2025 | Sale(10b5-1 plan) | −20,013 | $0.65 | $13.01K | 78,987 |
| Robert D. Allen III Chief Scientific Officer | Aug 18, 2025 | Sale(10b5-1 plan) | −18,512 | $0.65 | $12.03K | 80,488 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 18, 2025 | Sale(10b5-1 plan) | −33,352 | $0.65 | $21.68K | 133,848 |
| William E. Duke Chief Financial Officer | Aug 18, 2025 | Sale(10b5-1 plan) | −20,013 | $0.65 | $13.01K | 78,987 |
| Timothy Edward Lee Chief Commercial Officer | Aug 15, 2025 | Option exercise | +99,000 | – | – | 109,000 |
| Julie Green Chief Human Resources Officer | Aug 15, 2025 | Option exercise | +99,000 | – | – | 99,000 |
| Robert D. Allen III Chief Scientific Officer | Aug 15, 2025 | Option exercise | +99,000 | – | – | 99,000 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 15, 2025 | Option exercise | +165,000 | – | – | 167,200 |
| William E. Duke Chief Financial Officer | Aug 15, 2025 | Option exercise | +99,000 | – | – | 99,000 |
| Terrance McGuire Director | Dec 31, 2024 | Sale | −103,474 | $0.45 | $46.56K | 3,066,757 |
| Terrance McGuire Director | Dec 30, 2024 | Sale | −86,545 | $0.48 | $41.54K | 3,170,231 |
| Terrance McGuire Director | Dec 27, 2024 | Sale | −83,744 | $0.52 | $43.55K | 3,256,776 |
| Terrance McGuire Director | Dec 26, 2024 | Sale | −83,817 | $0.54 | $45.26K | 3,340,520 |
| Terrance McGuire Director | Dec 24, 2024 | Sale | −68,161 | $0.51 | $34.76K | 3,424,337 |
| Terrance McGuire Director | Dec 23, 2024 | Sale | −75,776 | $0.45 | $34.10K | 3,492,498 |
| Terrance McGuire Director | Dec 20, 2024 | Sale | −119,805 | $0.42 | $50.32K | 3,568,274 |
| Terrance McGuire Director | Dec 19, 2024 | Sale | −152,067 | $0.43 | $65.39K | 3,688,079 |
| Terrance McGuire Director | Dec 18, 2024 | Sale | −74,764 | $0.47 | $35.14K | 3,840,146 |
| Terrance McGuire Director | Dec 17, 2024 | Sale | −97,410 | $0.48 | $46.76K | 3,914,910 |
| Terrance McGuire Director | Dec 16, 2024 | Sale | −65,359 | $0.47 | $30.72K | 4,012,320 |
| Terrance McGuire Director | Dec 12, 2024 | Sale | −125,000 | $0.58 | $72.50K | 4,077,679 |
| Terrance McGuire Director | Dec 11, 2024 | Sale | −160,400 | $0.59 | $94.64K | 4,202,679 |
| Terrance McGuire Director | Dec 10, 2024 | Sale | −175,000 | $0.59 | $103.25K | 4,363,079 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Invivyd's stock actually held short. Settlement fails (shares not delivered on time) peaked at 117,372 shares on Oct 5, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Timothy Edward Lee Officer | Aug 17, 2026 | 40,800 | $29.41K | Aug 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Julie Green Officer | Aug 17, 2026 | 40,800 | $29.41K | Aug 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| William E. Duke Officer | Aug 17, 2026 | 40,800 | $29.41K | Aug 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Jill Andersen Officer | Aug 17, 2026 | 68,001 | $49.02K | Aug 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Robert D. Allen III Officer | Aug 17, 2026 | 37,741 | $27.21K | Aug 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Julie Green Officer | Feb 17, 2026 | 39,600 | $61.78K | Feb 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Robert D. Allen III Officer | Feb 17, 2026 | 36,630 | $57.14K | Feb 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Timothy Edward Lee Officer | Feb 17, 2026 | 39,600 | $61.78K | Feb 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| William E. Duke Officer | Feb 17, 2026 | 39,600 | $61.78K | Feb 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Jill Andersen Officer | Feb 17, 2026 | 66,000 | $102.96K | Feb 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Adimab, LLC 10% Stockholder | Dec 23, 2025 | 192,320 | $577.50K | Dec 23, 2025 | Private Acquisition from Issuer/Affiliate |
| Adimab, LLC 10% Stockholder | Nov 17, 2025 | 1,233,416 | $3.70M | Nov 17, 2025 | Private Acquisition from Issuer/Affiliate |
| Julie Green Officer | Aug 18, 2025 | 39,600 | $28.00K | Aug 18, 2025 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Robert D. Allen III Officer | Aug 18, 2025 | 36,631 | $25.90K | Aug 18, 2025 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Timothy Edward Lee Officer | Aug 18, 2025 | 39,600 | $28.00K | Aug 18, 2025 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
See a number that looks wrong?